3-(甲硫基)-1,2-苯二胺 | 351458-31-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 3-(甲硫基)-1,2-苯二胺
• 中文别名: 1,4-丁二硫醇,2,3-二氨基-
• 英文名称: 3-methylsulfanylbenzene-1,2-diamine
• 英文别名: 3-(methylthio)benzene-1,2-diamine
• CAS: 351458-31-6
• 化学式: C₇H₁₀N₂S
• 分子量: 154.236
• InChiKey: MAODRSNVSCQCBQ-UHFFFAOYSA-N

物化性质

• 沸点：
  292.5±25.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  77.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  3-(甲硫基)-1,2-苯二胺 在 chromium(VI) oxide 、 盐酸 、 溶剂黄146 作用下， 以 水 为溶剂， 反应 3.33h， 生成 1-(7-methylsulfanyl-1H-benzimidazol-2-yl)ethanone
  参考文献：
  名称：

  含有苯并五元不饱和杂环结构的α、β不饱和酮 类化合物及其制备方法和应用

  摘要：

  本发明提供公开了一类含有苯并五元不饱和杂环结构的α、β不饱和酮类化合物及其制备方法和用途，本发明的一类含有苯并五元不饱和杂环结构的α、β不饱和酮类化合物具有通式(Ⅰ)的结构。此外，本发明还提供了制备所述化合物的方法以及含有所述化合物作为活性成分的药物组合物。体外活性测试显示，本发明化合物表现出了对肿瘤细胞明显的抑制作用。因此，本发明为今后深入研究与开发抗肿瘤药物奠定了基础，同时也为肿瘤疾病的治疗提供了一种新的技术手段。

  公开号：

  CN104140415B
• 作为产物：
  描述：

  3-氯-2-硝基苯胺 在 tin(ll) chloride 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 3-(甲硫基)-1,2-苯二胺
  参考文献：
  名称：

  2-(Benzimidazol-2-yl)quinoxalines:  A Novel Class of Selective Antagonists at Human A₁ and A₃ Adenosine Receptors Designed by 3D Database Searching

  摘要：

  The Cambridge Structural Database (CSD) was searched through two 3D queries based on substructures shared by well-known antagonists at the A(1) and A(3) adenosine receptors (ARs). Among the resulting 557 hits found in the CSD, we selected five compounds to purchase, synthesize, or translate synthetically into analogues better tailored to interact with the biological targets. Binding experiments using human ARs showed that four out of five tested compounds turned out to be antagonists at the A(1)AR or A(3)AR with K-i values between 50 and 440 nM. Lead optimizations of 2-(benzimidazol-2-yl)quinoxalines (BIQs, 3) gave the best results in terms of potency and selectivity at the A(1) and A(3) ARs. Particularly, 2-(4-etliylthiobenzimidazol-2-yl)quinoxaline (3e) exhibited K-i values at the A(1)AR, A(2A)AR, and A(3)AR, of 0.5, 3440, and 955 nM, respectively, whereas 2-(4-methylbenzimidazol-2-yl)quinoxaline (3b) displayed at the same ARs K-i values of 8000, 833, and 26 nM, respectively.

  DOI：

  10.1021/jm050792d

文献信息

• [EN] NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS UTILES EN TANT QU'INHIBITEURS DE S100
  申请人：ACTIVE BIOTECH AB

  公开号：WO2015177367A1

  公开（公告）日：2015-11-26

  A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.

  式（I）的化合物或其药用盐以及包含该化合物的药物组合物。该化合物是S100A9与相互作用伙伴（如RAGE、TLR4和EMMPRIN）之间相互作用的抑制剂，因此在治疗癌症、自身免疫性疾病、炎症性疾病和神经退行性疾病等疾病方面是有用的。
• Derivatives of Benzimidazol-2-ylquinoline and Benzimidazol-2-ylisoquinoline as Selective A1 Adenosine Receptor Antagonists with Stimulant Activity on Human Colon Motility
  作者：Barbara Cosimelli、Sabrina Taliani、Giovanni Greco、Ettore Novellino、Annalisa Sala、Elda Severi、Federico Da Settimo、Concettina La Motta、Isabella Pugliesi、Luca Antonioli、Matteo Fornai、Rocchina Colucci、Corrado Blandizzi、Simona Daniele、Maria Letizia Trincavelli、Claudia Martini

  DOI：10.1002/cmdc.201100284

  日期：2011.10.4

  novel antagonists of adenosine receptors (ARs) by competition experiments using human A1, A2A, and A3 ARs. The new compounds were designed based on derivatives of 2‐(benzimidazol‐2‐yl)quinoxaline, previously reported as potent and selective antagonists of A1 and A3 ARs. Among these, 3‐[4‐(ethylthio)‐1H‐benzimidazol‐2‐yl]isoquinoline 4 b exhibited the best combination of potency toward the A1 AR (Ki=1

  通过使用人A 1，A 2A和A 3 AR进行竞争实验，合成了许多以各种方式连接到取代的苯并咪唑-2-基系统的喹啉和异喹啉，并将其评价为新型腺苷受体（ARs）拮抗剂。新化合物是基于2-（苯并咪唑-2-基）喹喔啉的衍生物设计的，该衍生物以前被报道为A 1和A 3 AR的有效和选择性拮抗剂。其中，3- [4-（乙硫基）-1 H-苯并咪唑-2-基]异喹啉4b表现出对A 1 AR（K i = 1.4 n M）和对A 2A（K i > 10μm）， A 2B（K i > 10μm）和A 3 ARs（K i > 1μM）的选择性。在分离的人结肠的圆形平滑肌制剂中的功能实验表明，4b在该肠区域的神经肌肉区室中充当A 1 AR的有效和选择性拮抗剂。生物学和药理学数据表明4b是开发具有结肠活动刺激特性的新型药物的合适起点。
• Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
  申请人：Reich Heinz Siegfried

  公开号：US20050239855A1

  公开（公告）日：2005-10-27

  Indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating, e.g., kinases-dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  本文描述了调节和/或抑制细胞增殖的吲唑化合物，例如蛋白激酶的活性。这些化合物和含有它们的药物组合物能够介导依赖于激酶的疾病，以调节和/或抑制不想要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予有效量的这些化合物治疗癌症以及其他与不想要的血管生成和/或细胞增殖相关的疾病状态，如糖尿病性视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
• Method of producing benzamide derivatives
  申请人：MITSUI CHEMICALS, INC.

  公开号：EP0974576A2

  公开（公告）日：2000-01-26

  In the case that a selectively monoacylated phenylenediamine derivative of the following formula: wherein R1, R2, R3 and R10 have the meanings given in the description which is useful as any of medicines, agricultural chemicals, animal drugs and the intermediates of chemicals is prepared by reacting a benzoic acid derivative with a phenylenediamine derivative, the benzoic acid derivative is converted into a benzoyl imidazole derivative and this benzoyl imidazole derivative is then reacted with the phenylenediamine derivative, whereby the improvement of a preparation efficiency and the high selectivity of the monoacylation can be achieved, the steps of protection and deprotection being omitted.

  如果下式为选择性单乙酰化苯二胺衍生物： 其中 R1、R2、R3 和 R10 具有说明中给出的含义，该衍生物可用作药物、农药、动物用药和化学中间体中的任何一种，是通过苯甲酸衍生物与苯二胺衍生物反应制备的、将苯甲酸衍生物转化为苯甲酰基咪唑衍生物，然后将苯甲酰基咪唑衍生物与苯二胺衍生物反应，从而提高制备效率和单酰化的高选择性，省略保护和脱保护步骤。
• INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE FOR MEDIATING OR INHIBITING CELL PROLIFERATION
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：EP1250326A2

  公开（公告）日：2002-10-23